Deciphera Pharmaceuticals’ (DCPH) “Hold” Rating Reiterated at Jonestrading

Deciphera Pharmaceuticals (NASDAQ:DCPH)‘s stock had its “hold” rating reiterated by investment analysts at Jonestrading in a report released on Monday, Benzinga reports. They presently have a $25.60 target price on the stock. Jonestrading’s price objective suggests a potential upside of 1.31% from the stock’s current price.

A number of other research analysts have also recently commented on DCPH. Stifel Nicolaus upped their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. upped their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $24.17.

Deciphera Pharmaceuticals Price Performance

Shares of DCPH stock opened at $25.27 on Monday. The company has a market capitalization of $2.08 billion, a PE ratio of -11.03 and a beta of 0.39. The firm’s 50-day moving average is $15.98 and its two-hundred day moving average is $14.55. Deciphera Pharmaceuticals has a 12 month low of $9.90 and a 12 month high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter last year, the firm earned ($0.60) earnings per share. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. Sell-side analysts forecast that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Institutional Trading of Deciphera Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its position in shares of Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock worth $16,482,000 after acquiring an additional 651,800 shares in the last quarter. Armistice Capital LLC boosted its holdings in Deciphera Pharmaceuticals by 12.7% in the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $83,876,000 after purchasing an additional 588,000 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Deciphera Pharmaceuticals by 14.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after purchasing an additional 290,968 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after purchasing an additional 190,580 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its holdings in Deciphera Pharmaceuticals by 157.1% during the fourth quarter. Panagora Asset Management Inc. now owns 235,845 shares of the company’s stock worth $3,804,000 after purchasing an additional 144,097 shares in the last quarter. 70.96% of the stock is currently owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.